Detailed Indications for Repotrectinib

Detailed Indications for Repotrectinib

One core indication of Repotrectinib is the treatment of ROS1-positive non-small cell lung cancer. Specifically, it is indicated for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. These patients harbor ROS1 gene fusions in their tumors, which are key molecular abnormalities driving tumor growth. As a next-generation tyrosine kinase inhibitor, Repotrectinib targets and inhibits ROS1 activity, thereby controlling tumor progression. Clinical trials have shown that the drug demonstrates significant efficacy in both treatment-naïve and previously treated patients with ROS1-positive non-small cell lung cancer, and it is particularly active against resistant tumors harboring solvent front mutations.

Use in NTRK Gene Fusion-Positive Solid Tumors

Additionally, Repotrectinib is indicated for pediatric (aged 12 years and older) and adult patients with solid tumors that meet specific criteria: the tumor must harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion; the tumor is locally advanced or metastatic, or surgical resection is likely to result in severe complications; the patient has progressed following prior treatment, or there is no satisfactory alternative therapy. This indication covers various solid tumor types that may carry NTRK fusions, such as salivary gland cancer, sarcoma, thyroid cancer, etc., reflecting a "tumor-agnostic" treatment approach.

Approval of Repotrectinib

The above indication for NTRK gene fusion-positive solid tumors received accelerated approval from the U.S. Food and Drug Administration based on overall response rate and duration of response. This means that continued approval for this indication may depend on verification and description of clinical benefit in subsequent confirmatory trials. Before confirmatory trials are completed, physicians and patients should fully understand the benefit-risk profile of the drug for this indication. The accelerated approval mechanism provides patients with earlier access to promising innovative therapies while requiring manufacturers to continue research to confirm long-term clinical value.